BHC

Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.

Wall Street analysts forecast BHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHC is 8.50 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Bausch Health Companies Inc revenue for the last quarter amounts to 2.68B USD, increased 6.81 % YoY.

Bausch Health Companies Inc. EPS for the last quarter amounts to 0.48 USD, decreased -308.70 % YoY.

Bausch Health Companies Inc (BHC) has 20700 emplpoyees as of December 16 2025.

Today BHC has the market capitalization of 2.56B USD.